Dispatch: IOM Tells FDA What It Wants to Hear
The Institute of Medicine (IOM) yesterday released a report on biomarkers, which are characteristics that indicate biological processes; e.g., high cholesterol as an indicator of the development of heart disease. According to the IOM, “[T]he Food and Drug Administration (FDA) asked the IOM to conduct a study on the evaluation process for biomark¬ers, focusing on biomarkers and surrogate endpoints in chronic disease.
